89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma
Open Access
- 19 February 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 258
Abstract
Background: Indeterminate renal masses (IRMs) frequently require biopsy for characterization and often lead to unnecessary surgical interventions. 89Zr-girentuximab is a positron emission tomography (PET) radiopharmaceutical targeting carbonic anhydrase IX, a biomarker overexpressed in clear-cell renal cell carcinoma (ccRCC). This real-world experience demonstrates the impact of 89Zr-girentuximab PET on the clinical management of patients with IRM and its role in differentiating primary and metastatic ccRCC from other etiologies. Methods: This prospective single-center study, part of an expanded access program (NCT06090331), investigated patients with IRM on conventional imaging who underwent 89Zr-girentuximab PET/computed tomography (PET/CT). Qualitative and quantitative PET/CT features of each lesion were assessed. Pathologic or clinical diagnosis was determined for all lesions. Referring physicians were surveyed to evaluate the impact of PET on patient management. Results: Seven male patients (age range, 57–78 years) were included; four had ccRCC (including two with metastatic disease) and three had oncocytoma (including one with Birt-Hogg-Dubé syndrome). Across all 32 lesions identified, 89Zr-girentuximab PET/CT accurately characterized each lesion based on pathologic or clinical diagnosis. 89Zr-girentuximab PET/CT identified ccRCC tumor thrombi in the inferior vena cava and renal vein branches (SUVmax 12.0–13.0), a perinephric deposit (SUVmax 36.4), and intramuscular (SUVmax 103.0), pulmonary (SUVmax 4.0–10.5), and osseous (SUVmax 10.2) metastases. 89Zr-girentuximab PET/CT enabled the diagnosis of oncocytomatosis in one patient and detected a renal lesion with positive uptake that was occult on MRI. According to referring physicians, 89Zr-girentuximab PET/CT changed clinical management in six of seven patients and improved patient care in all cases. Conclusions: 89Zr-girentuximab PET/CT provides a noninvasive tool for characterizing indeterminate renal masses and metastatic ccRCC and may improve clinical problem-solving in complex scenarios.Keywords
Funding Information
- Telix Pharmaceuticals (NCT06090331)
- National Cancer Institute (K08CA259626)
- National Cancer Institute (K08CA249047)
This publication has 20 references indexed in Scilit:
- Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?Expert Review of Anticancer Therapy, 2025
- [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialThe Lancet Oncology, 2024
- The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and SubtypeEuropean Urology Open Science, 2023
- Novel Imaging Methods for Renal Mass Characterization: A Collaborative ReviewEuropean Urology, 2022
- Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized CohortEuropean Urology, 2020
- Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Association of Prevalence of Benign Pathologic Findings After Partial Nephrectomy With Preoperative Imaging Patterns in the United States From 2007 to 2014JAMA Surgery, 2019
- Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma SuspicionEuropean Urology, 2018
- Incompletely Characterized Incidental Renal Masses: Emerging Data Support Conservative ManagementRadiology, 2015
- Identification of the MN/CA9 Protein as a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the KidneyJournal of Urology, 1998